These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24621463)

  • 1. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome.
    Nakagami H; Pang Z; Shimosato T; Moritani T; Kurinami H; Koriyama H; Tenma A; Shimamura M; Morishita R
    Hypertens Res; 2014 Jul; 37(7):629-35. PubMed ID: 24621463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
    Fukuda-Tsuru S; Kakimoto T; Utsumi H; Kiuchi S; Ishii S
    Eur J Pharmacol; 2014 Jan; 723():207-15. PubMed ID: 24309217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats.
    Kimura S; Inoguchi T; Yamasaki T; Yamato M; Ide M; Sonoda N; Yamada K; Takayanagi R
    Metabolism; 2016 Mar; 65(3):138-45. PubMed ID: 26892525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory.
    Pujadas G; De Nigris V; Prattichizzo F; La Sala L; Testa R; Ceriello A
    Endocrine; 2017 Jun; 56(3):509-520. PubMed ID: 27530507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
    Jackson EK; Dubinion JH; Mi Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Takahara Y; Tokunou T; Ichiki T
    J Atheroscler Thromb; 2018 Aug; 25(8):698-708. PubMed ID: 29321388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: The Contribution of Glucagon-like Peptide-1.
    Moroi M; Kubota T
    J Cardiovasc Pharmacol; 2015 Aug; 66(2):159-64. PubMed ID: 25853991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
    Ito R; Fukui T; Hayashi T; Osamura A; Ohara M; Hara N; Higuchi A; Yamamoto T; Hirano T
    Drugs R D; 2015 Sep; 15(3):245-51. PubMed ID: 26224337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice.
    Nakamura K; Fukunishi S; Yokohama K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2017 Apr; 39(4):969-983. PubMed ID: 28260070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
    Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
    Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teneligliptin : expectations for its pleiotropic action.
    Morishita R; Nakagami H
    Expert Opin Pharmacother; 2015 Feb; 16(3):417-26. PubMed ID: 25597385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-intensity voluntary running lowers blood pressure with simultaneous improvement in endothelium-dependent vasodilatation and insulin sensitivity in aged spontaneously hypertensive rats.
    Sun MW; Qian FL; Wang J; Tao T; Guo J; Wang L; Lu AY; Chen H
    Hypertens Res; 2008 Mar; 31(3):543-52. PubMed ID: 18497475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp.
    Hussein G; Nakagawa T; Goto H; Shimada Y; Matsumoto K; Sankawa U; Watanabe H
    Life Sci; 2007 Jan; 80(6):522-9. PubMed ID: 17074368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages.
    Hiromura M; Nohtomi K; Mori Y; Kataoka H; Sugano M; Ohnuma K; Kuwata H; Hirano T
    Biochem Biophys Res Commun; 2018 Jan; 495(1):223-229. PubMed ID: 29113797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury.
    Zhang Z; Jin X; Yang C; Li Y
    Biomed Pharmacother; 2019 Jan; 109():468-474. PubMed ID: 30399583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome.
    Kagota S; Yamaguchi Y; Tanaka N; Kubota Y; Kobayashi K; Nejime N; Nakamura K; Kunitomo M; Shinozuka K
    Life Sci; 2006 Feb; 78(11):1187-96. PubMed ID: 16188278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity.
    Sameshima A; Wada T; Ito T; Kashimura A; Sawakawa K; Yonezawa R; Tsuneki H; Ishii Y; Sasahara M; Saito S; Sasaoka T
    J Endocrinol; 2015 Oct; 227(1):25-36. PubMed ID: 26264980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.